Complex Disease Treatment Market, By Disease (Asthma, Diabetes, Epilepsy, Hypertension, Manic Depression, Schizophrenia, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI265119 | Publish Date: May 2024 | No. of Pages: 178

Global Complex Disease Treatment Market Overview

Complex Disease Treatment Market was valued at US$ 244.4 billion in 2024 and is projected to grow at a CAGR of 13.1% to reach US$ 748.5 billion by 2034.

Complex diseases are the diseases that run common in families and are caused by combination of environmental, lifestyle, and genetic factors. Complex diseases include diabetes, asthma, epilepsy, manic depression, schizophrenia, and hypertension. Some abnormalities are included which involves congenital heart defects and cleft lip. Rising prevalence of the complex diseases like epilepsy, asthma, diabetes, etc. are the key factors driving the global complex disease treatment market.

Drug

Disease

Approval year

Dupixent

Asthma

October 2018

Ozempic

Type II Diabetes

December 2017

Briviact

Epilepsy

February 2016

Vraylar

Schizophrenia

September 2015

Lithobid

Manic Depression

January 1996

 

In the global complex diseases treatment market, recent drugs approved include Dupixent, Ozempic, Briviact, Vraylar, and Lithobid.

Global complex disease treatment market report published by Prophecy Market Insights offers holistic view of various influencing factors and aims to answer all the target market related questions.

The research scope provides comprehensive market size, and other in-depth market information details such as, market growth supporting factors, restraining factors, trends, opportunities, market risk factors, market competition, product and services advancements and launches, product/services related regulations overview, and recent developments for the mentioned forecast period. In addition, the report provides key examination of market players operating in the specific market and analysis and outcomes related with the target market for more than 20 countries.

In the current research scope 2018 is considered as base year and 2019 is estimated year for market value/volume calculations. The report offers market estimates for the forecast period – 2019 to 2029. The report provides factual inputs and analysis based on primary and secondary research, which includes insights gained through in-depth interviews with primary research participants. Also, the data is gathered from authentic secondary sources and is verified by key opinion leaders in the target market. The in-house research is applied on gathered information to provide more accurate data points and reduce the margin of error. The in-house research and analysis efforts include various tools and 360o data analysis methodology.

Introduction - Complex Disease Treatment Market

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Global Complex Disease Treatment Market Drivers & Restraints

Complex Disease Treatment Market Key Drivers:
 
Rising Prevalence of Complex Diseases

Globally, the prevalence of diseases including diabetes, asthma, and cancer is rising as a result of a number of causes including aging populations, shifting lifestyles, and exposure to the environment. The market is growing because of the rising need for therapy. The target market has also expanded as a result of new pharmacological developments and innovative ways to treat.

Complex Disease Treatment Market Restrains:

High Treatment Costs

Complex disorders may call for expensive, long-term therapies including specialist drugs, cutting-edge diagnostics, and cutting-edge equipment. For many patients, the cost barrier prevents them from receiving care. In addition, new drugs and technology must frequently pass long and complicated regulatory approval procedures before they can be sold, which drives up costs and delays availability.

Recent Development:

  • In November 2021, Novartis Pharma K.K. received approval in Japan for ENTREST 100 mg and 200 mg Tablets (generic name: sacubitril valsartan sodium hydrate) for the new indication of hypertension, according to Otsuka Pharmaceutical Co., Ltd. This is the first ARNI approval for the indication of hypertension in Japan.

Global Complex Disease Treatment Market Segmentations & Regional Insights

The global complex disease treatment market report segments the market on the basis of diseases and region.

The report expected to answer various target market related questions and offers insights on:

  • Definition, description, overview of market growth influencing factors, and forecast for the target market
  • Scope for related market in the forecast period
  • Analysis and outcome for the global complex disease treatment market by segment and region followed by countries
  • Market segmentation, dominating segment and region followed by country along with market value, share, Y-o-Y growth, CAGR, forecast, and contribution in the market
  • Key market player profiles, their recent developments, strategies, financial details, key competencies, presence by region, and product portfolio
  • Valuable insights, data, and forecast that can be referenced to plan business strategies, to tap market opportunities, understand business related risks, derive business goals, to recognize trends, and understand target customers/end users
  • Insights on recent technologies, pipeline products, regulations related with target market, market investment, and offers insights on political and economic factors that may influence market growth
  • PEST Analysis, PORTER’s five forces analysis, opportunity map analysis, drivers and restraints impact analysis, and market attractiveness index.

Report Scope:

Attribute

Details

Market Size 2024

US$ 244.4 billion

Projected Market Size 2034

US$ 748.5 billion

CAGR Growth Rate

13.1%

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Disease - Asthma, Diabetes, Epilepsy, Hypertension, Manic Depression, Schizophrenia, and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Global Complex Disease Treatment Market Competitive Landscape & Key Players

The Key players operating in the complex disease treatment market includes Regeneron Pharmaceuticals, Inc., Novo Nordisk A/S, UCB SA, Solvay Pharmaceuticals, Inc., Allergan plc, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Celgene Corporation, and AbbVie Inc.

Global Complex Disease Treatment Market Company Profile

  • Regeneron Pharmaceuticals, Inc.
  • Novo Nordisk A/S
  • UCB SA
  • Solvay Pharmaceuticals, Inc.
  • Allergan plc
  • Novartis AG
  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Celgene Corporation
  • AbbVie, Inc.

Prophecy Market Insights offers required customization on this report according to specific business requirements.